Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01743157 · ClinicalTrials.gov registry record · Phase 1
Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma
A Phase 1 study, sponsored by California Pacific Medical Center Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01743157 is a Phase 1 study that has completed, run by California Pacific Medical Center Research Institute. The registered enrollment target is 24 participants.
The verdict
NCT01743157, a Phase 1 study, has completed, sponsored by California Pacific Medical Center Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy plus Bevacizumab followed by consolidation therapy with Ipilimumab (BBI).
Interventions
- DRUG Biochemo + bevacizumab then ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01743157
The ClinicalTrials.gov registry entry for NCT01743157 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is California Pacific Medical Center Research Institute, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biochemo + bevacizumab then ipilimumab is the first listed.
NCT01743157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01743157 about?
NCT01743157 is a clinical study titled "Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma". A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy plus Bevacizumab followed by consolidation therapy with Ipilimumab (BBI).
What is the current status of trial NCT01743157?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-12. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01743157?
The interventions under investigation include: Biochemo + bevacizumab then ipilimumab (DRUG).
Who is sponsoring clinical trial NCT01743157?
This trial is sponsored by California Pacific Medical Center Research Institute, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.